Thaci, Diamant, Kenneth Gordon, Melinda Gooderham, Bruce Strober, Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, and Akimichi Morita. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 5, no. 6 (November 5, 2021): s37. Accessed August 12, 2022.